9MW 2821
Alternative Names: 9MW-2821Latest Information Update: 29 Aug 2024
At a glance
- Originator Mabwell (Shanghai) Bioscience
- Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Urogenital cancer
- Phase I/II Solid tumours
- Phase I Bladder cancer
Most Recent Events
- 25 Aug 2024 Phase-III clinical trials in Urogenital cancer (First-line therapy, Metastatic disease, Late-stage disease, Combination therapy) (IV)
- 25 Aug 2024 Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approves CTA for 9MW 2821 in Urogenital cancer
- 23 Aug 2024 Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approves CTA for 9MW 2821 in Cervical cancer